Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 4 |
| List of Tables | 5 | 1 |
| List of Figures | 5 | 1 |
| Introduction | 6 | 1 |
| Global Markets Direct Report Coverage | 6 | 1 |
| Familial Amyloid Neuropathies Overview | 7 | 1 |
| Therapeutics Development | 8 | 2 |
| Pipeline Products for Familial Amyloid Neuropathies Overview | 8 | 1 |
| Pipeline Products for Familial Amyloid Neuropathies Comparative Analysis | 9 | 1 |
| Familial Amyloid Neuropathies Therapeutics under Development by Companies | 10 | 1 |
| Familial Amyloid Neuropathies Therapeutics under Investigation by Universities/Institutes | 11 | 1 |
| Familial Amyloid Neuropathies Pipeline Products Glance | 12 | 3 |
| Late Stage Products | 12 | 1 |
| Clinical Stage Products | 13 | 1 |
| Early Stage Products | 14 | 1 |
| Familial Amyloid Neuropathies Products under Development by Companies | 15 | 1 |
| Familial Amyloid Neuropathies Products under Investigation by Universities/Institutes | 16 | 1 |
| Familial Amyloid Neuropathies Companies Involved in Therapeutics Development | 17 | 5 |
| Alnylam Pharmaceuticals, Inc. | 17 | 1 |
| Bsim2 | 18 | 1 |
| GlaxoSmithKline Plc | 19 | 1 |
| Pfizer Inc. | 20 | 1 |
| SOM Innovation Biotech SL | 21 | 1 |
| Familial Amyloid Neuropathies Therapeutics Assessment | 22 | 9 |
| Assessment by Monotherapy Products | 22 | 1 |
| Assessment by Target | 23 | 2 |
| Assessment by Mechanism of Action | 25 | 2 |
| Assessment by Route of Administration | 27 | 2 |
| Assessment by Molecule Type | 29 | 2 |
| Drug Profiles | 31 | 16 |
| CLR-01 - Drug Profile | 31 | 1 |
| Product Description | 31 | 1 |
| Mechanism of Action | 31 | 1 |
| R&D Progress | 31 | 2 |
| doxycycline hyclate - Drug Profile | 33 | 1 |
| Product Description | 33 | 1 |
| Mechanism of Action | 33 | 1 |
| R&D Progress | 33 | 1 |
| inotersen sodium - Drug Profile | 34 | 1 |
| Product Description | 34 | 1 |
| Mechanism of Action | 34 | 1 |
| R&D Progress | 34 | 2 |
| Monoclonal Antibody to Inhibit ATTR for Familial Amyloid Polyneuropathy - Drug Profile | 36 | 1 |
| Product Description | 36 | 1 |
| Mechanism of Action | 36 | 1 |
| R&D Progress | 36 | 1 |
| patisiran - Drug Profile | 37 | 1 |
| Product Description | 37 | 1 |
| Mechanism of Action | 37 | 1 |
| R&D Progress | 37 | 1 |
| revusiran - Drug Profile | 38 | 1 |
| Product Description | 38 | 1 |
| Mechanism of Action | 38 | 1 |
| R&D Progress | 38 | 3 |
| Small Molecules to Inhibit Transthyretin for Familial Amyloid Polyneuropathy - Drug Profile | 41 | 1 |
| Product Description | 41 | 1 |
| Mechanism of Action | 41 | 1 |
| R&D Progress | 41 | 1 |
| Small Molecules to Inhibit Transthyretin Related Amyloid Protein for Familial Amyloidotic Polyneuropathy - Drug Profile | 42 | 1 |
| Product Description | 42 | 1 |
| Mechanism of Action | 42 | 1 |
| R&D Progress | 42 | 1 |
| tafamidis meglumine - Drug Profile | 43 | 1 |
| Product Description | 43 | 1 |
| Mechanism of Action | 43 | 1 |
| R&D Progress | 43 | 2 |
| tolcapone - Drug Profile | 45 | 1 |
| Product Description | 45 | 1 |
| Mechanism of Action | 45 | 1 |
| R&D Progress | 45 | 2 |
| Familial Amyloid Neuropathies Recent Pipeline Updates | 47 | 15 |
| Familial Amyloid Neuropathies - Dormant Projects | 62 | 1 |
| Familial Amyloid Neuropathies Product Development Milestones | 63 | 12 |
| Featured News &Press Releases | 63 | 1 |
| May 26, 2016: Ionis Pharmaceuticals Provides Update on IONIS-TTR Rx Program | 63 | 1 |
| Apr 20, 2016: Alnylam Reports Complete 18-Month Data from Ongoing Phase 2 Open-Label Extension Study of Patisiran, an Investigational RNAi Therapeutic Targeting Transthyretin for the Treatment of Hereditary ATTR Amyloidosis with Polyneuropathy (hATTR-PN) | 63 | 2 |
| Feb 01, 2016: Alnylam Completes Enrollment in APOLLO Phase 3 Study with Patisiran, an Investigational RNAi Therapeutic for Patients with Transthyretin (TTR)-Mediated Amyloidosis (ATTR Amyloidosis) | 65 | 1 |
| Dec 17, 2015: Isis Pharmaceuticals Announces Initiation of an Investigator-Sponsored Phase 2 Study of ISIS-TTR Rx in Patients with TTR Cardiomyopathy Amyloidosis | 66 | 1 |
| Nov 03, 2015: Isis Pharmaceuticals Reports an Update on ISIS-TTR Rx, Including Positive Data from Multiple Clinical Studies, Presented at the EC-ATTR Meeting | 67 | 1 |
| Nov 03, 2015: Alnylam Reports Positive Results from Ongoing Phase 2 Open-Label Extension Studies for Patisiran in Development for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis (ATTR Amyloidosis) | 68 | 2 |
| Nov 03, 2015: Alnylam Reports Positive Results from Ongoing Phase 2 Open-Label Extension Studies for Revusiran, in Development for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis | 70 | 1 |
| Oct 27, 2015: Isis Pharmaceuticals to Host Webcast to Review ISIS-TTR Data Presented at 1st European Congress of Hereditary ATTR Amyloidosis and Provide Phase 3 Development Plan Update | 71 | 1 |
| Sep 28, 2015: Alnylam and Collaborators Report First-Ever Evidence that Patisiran Reduces Pathogenic, Misfolded Transthyretin Monomers and Oligomers in TTR-Mediated Amyloidosis Patients with Familial Amyloidotic Polyneuropathy | 71 | 2 |
| Jul 20, 2015: Alnylam Initiates Phase 3 Open Label Extension Study with Patisiran, an Investigational RNAi Therapeutic Targeting Transthyretin for the Treatment of TTR-Mediated Amyloidosis | 73 | 2 |
| Appendix | 75 | 2 |
| Methodology | 75 | 1 |
| Coverage | 75 | 1 |
| Secondary Research | 75 | 1 |
| Primary Research | 75 | 1 |
| Expert Panel Validation | 75 | 1 |
| Contact Us | 75 | 1 |
| Disclaimer | 76 | 1 |